El Dr. Carsten Niederlander, nuevo Director de Desarrollo Farmacéutico

Barcelona, 4 May 2006.- Almirall announces the appointment of Dr Carsten Niederlaender as Director of Pharmaceutical Development, reporting to the Executive Director for the R&D Area, Dr Per Olof Andersson.The appointment is a further example of Almirall’s commitment to the development of its R&D area.

Dr Carsten Niederlander has a PhD in Chemistry from the University of Saarbrücken, Germany.He has established his professional career within the pharmaceutical sector in multinational companies such as Sandoz Pharma AG (Switzerland), Novartis Pharma (UK) and SkyePharma AG (Switzerland), in areas focused on the pharmaceutical development closely linked to the respiratory area. This is one of Almirall’s R&D focal points, as shown by the development progression of the LAS34273, its new therapy for COPD (chronic obstructive pulmonary disease).

Almirall, a leading company committed to health

Almirall is an international pharmaceutical company that researches, develops and commercialises its own R&D and licensed specialities with the aim of improving health and quality of life. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis and rheumatoid arthritis.

Almirall is currently present in approximately 100 countries with its own products and licensed products from other prestigious companies.The company is strengthening its direct presence in Europe and Latin America via affiliates.